tiprankstipranks
Advertisement
Advertisement

PMVP Stock Latest News

PMV Pharmaceuticals price target lowered to $4 from $16 at Evercore ISI
The FlyPMV Pharmaceuticals price target lowered to $4 from $16 at Evercore ISI
4d ago
PMVP
PMV Pharmaceuticals Advances Rezatapopt Interaction Study, Signaling Steady Progress in TP53-Driven Oncology
PremiumCompany Announcements
PMV Pharmaceuticals Advances Rezatapopt Interaction Study, Signaling Steady Progress in TP53-Driven Oncology
1M ago
PMVP
PMV Pharmaceuticals reports FY25 EPS ($1.48), consensus ($1.51)
PremiumThe Fly
PMV Pharmaceuticals reports FY25 EPS ($1.48), consensus ($1.51)
1M ago
PMVP
PMV Pharmaceuticals sees cash runway to end of 2Q27
PremiumThe Fly
PMV Pharmaceuticals sees cash runway to end of 2Q27
1M ago
PMVP
Pmv Pharmaceuticals, Inc. (PMVP) Q4 Earnings Cheat Sheet
PremiumPre-Earnings
Pmv Pharmaceuticals, Inc. (PMVP) Q4 Earnings Cheat Sheet
2M ago
PMVP
PMV Pharmaceuticals announces results of Phase 1 trial of rezatapopt in NEJM
PremiumThe FlyPMV Pharmaceuticals announces results of Phase 1 trial of rezatapopt in NEJM
2M ago
PMVP
PMV Pharmaceuticals Reports Increased Quarterly Loss
Premium
Company Announcements
PMV Pharmaceuticals Reports Increased Quarterly Loss
5M ago
PMVP
Promising Developments in PMV Pharmaceuticals’ PYNNACLE Phase 2 Trial Boost Buy Rating
Premium
Ratings
Promising Developments in PMV Pharmaceuticals’ PYNNACLE Phase 2 Trial Boost Buy Rating
5M ago
PMVP
Buy Rating Affirmed for PMV Pharmaceuticals Amid Stable Financials and Strategic Growth Potential
PremiumRatings
Buy Rating Affirmed for PMV Pharmaceuticals Amid Stable Financials and Strategic Growth Potential
5M ago
PMVP
PMV Pharmaceuticals reports Q3 EPS (40c), consensus (40c)
PremiumThe Fly
PMV Pharmaceuticals reports Q3 EPS (40c), consensus (40c)
5M ago
PMVP
PMV Pharmaceuticals Advances Cancer Treatment with Promising Study on PC14586
PremiumCompany Announcements
PMV Pharmaceuticals Advances Cancer Treatment with Promising Study on PC14586
6M ago
PMVP
Promising Developments in PMV Pharmaceuticals’ Ovarian Cancer Treatment Drive Buy Rating
PremiumRatings
Promising Developments in PMV Pharmaceuticals’ Ovarian Cancer Treatment Drive Buy Rating
6M ago
PMVP
PMV Pharmaceuticals announces updated rezatapopt monotherapy interim data
PremiumThe FlyPMV Pharmaceuticals announces updated rezatapopt monotherapy interim data
6M ago
PMVP
Promising Phase 2 Trial Results and Strategic Plans Support Buy Rating for PMV Pharmaceuticals
Premium
Ratings
Promising Phase 2 Trial Results and Strategic Plans Support Buy Rating for PMV Pharmaceuticals
7M ago
PMVP
PMV Pharmaceuticals Reports Promising Phase 2 Trial Results
Premium
Company Announcements
PMV Pharmaceuticals Reports Promising Phase 2 Trial Results
7M ago
8K
PMVP
PMV Pharmaceuticals announces interim data from Phase 2 portion of PYNNACLE
PremiumThe Fly
PMV Pharmaceuticals announces interim data from Phase 2 portion of PYNNACLE
7M ago
PMVP
PMV Pharmaceuticals Reports Q2 2025 Financial Results
PremiumCompany Announcements
PMV Pharmaceuticals Reports Q2 2025 Financial Results
8M ago
PMVP
PMV Pharmaceuticals reports Q2 EPS (41c), consensus (38c)
PremiumThe Fly
PMV Pharmaceuticals reports Q2 EPS (41c), consensus (38c)
8M ago
PMVP
PMV Pharmaceuticals Holds 2025 Annual Stockholder Meeting
PremiumCompany Announcements
PMV Pharmaceuticals Holds 2025 Annual Stockholder Meeting
10M ago
8K
PMVP
PMV Pharmaceuticals Reports Q1 2025 Financial Results
PremiumCompany AnnouncementsPMV Pharmaceuticals Reports Q1 2025 Financial Results
11M ago
PMVP
PMV Pharmaceuticals reports Q1 EPS (34c), consensus (38c)
Premium
The Fly
PMV Pharmaceuticals reports Q1 EPS (34c), consensus (38c)
11M ago
PMVP
PMV Pharmaceuticals sees cash runway to end of 2026
Premium
The Fly
PMV Pharmaceuticals sees cash runway to end of 2026
11M ago
PMVP

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >